Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.

Conversion of low-affinity to high-affinity peptide by a beta-hairpin scaffold-assisted approach.

Preparation and therapeutic evaluation of paclitaxel-conjugated low-molecular-weight chitosan nanoparticles.

Synthesis and therapeutic evaluation of an aptide–docetaxel conjugate targeting tumor-associated fibronectin.

Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages.

Glycyrrhizin Enhances Therapeutic Activity of a Colon-Specific Methylprednisolone Prodrug Against Experimental Colitis.

Senescence marker protein 30 deficiency increases Parkinson`s pathology by impairing astrocyte activation.

Colon-specific delivery of celecoxibis a potential strategy to improve toxicological and pharmacological properties of the selective COX-2 inhibitor: implication in treatment of familiar adenomatous polyposis.

Preparation and in vitro evaluation of celecoxib-amino acid conjugates as a colon specific prodrug.

N-succinylaspart-1-yl celecoxib is a potential colon specific prodrug of celecoxib with improved therapeutic properties.